nodes	percent_of_prediction	percent_of_DWPC	metapath
Etodolac—RXRA—thyroid cancer	0.55	0.875	CbGaD
Etodolac—UGT2B7—Epirubicin—thyroid cancer	0.0955	0.391	CbGbCtD
Etodolac—UGT1A9—Sorafenib—thyroid cancer	0.0884	0.362	CbGbCtD
Etodolac—PTGS2—thyroid cancer	0.0786	0.125	CbGaD
Etodolac—ALB—Vandetanib—thyroid cancer	0.0455	0.186	CbGbCtD
Etodolac—CYP2C9—Sorafenib—thyroid cancer	0.0148	0.0605	CbGbCtD
Etodolac—Rash maculo-papular—Epirubicin—thyroid cancer	0.000213	0.00234	CcSEcCtD
Etodolac—Mouth ulceration—Epirubicin—thyroid cancer	0.000212	0.00233	CcSEcCtD
Etodolac—Ecchymosis—Epirubicin—thyroid cancer	0.000212	0.00233	CcSEcCtD
Etodolac—Bladder pain—Epirubicin—thyroid cancer	0.000212	0.00233	CcSEcCtD
Etodolac—Melaena—Doxorubicin—thyroid cancer	0.000212	0.00233	CcSEcCtD
Etodolac—Cystitis noninfective—Doxorubicin—thyroid cancer	0.000212	0.00233	CcSEcCtD
Etodolac—Rash—Vandetanib—thyroid cancer	0.000211	0.00233	CcSEcCtD
Etodolac—Dermatitis—Vandetanib—thyroid cancer	0.000211	0.00232	CcSEcCtD
Etodolac—Headache—Vandetanib—thyroid cancer	0.00021	0.00231	CcSEcCtD
Etodolac—Cystitis—Doxorubicin—thyroid cancer	0.000209	0.0023	CcSEcCtD
Etodolac—Colitis—Doxorubicin—thyroid cancer	0.000208	0.00229	CcSEcCtD
Etodolac—Skin exfoliation—Doxorubicin—thyroid cancer	0.000207	0.00228	CcSEcCtD
Etodolac—Musculoskeletal discomfort—Sorafenib—thyroid cancer	0.000206	0.00227	CcSEcCtD
Etodolac—Blood urea increased—Doxorubicin—thyroid cancer	0.000205	0.00225	CcSEcCtD
Etodolac—Aplastic anaemia—Doxorubicin—thyroid cancer	0.000204	0.00224	CcSEcCtD
Etodolac—Sepsis—Epirubicin—thyroid cancer	0.000203	0.00224	CcSEcCtD
Etodolac—Dyspnoea—Sorafenib—thyroid cancer	0.000202	0.00222	CcSEcCtD
Etodolac—Lymphadenopathy—Epirubicin—thyroid cancer	0.000199	0.00219	CcSEcCtD
Etodolac—Nausea—Vandetanib—thyroid cancer	0.000199	0.00219	CcSEcCtD
Etodolac—Dyspepsia—Sorafenib—thyroid cancer	0.000199	0.00219	CcSEcCtD
Etodolac—Coma—Doxorubicin—thyroid cancer	0.000198	0.00218	CcSEcCtD
Etodolac—Oesophagitis—Doxorubicin—thyroid cancer	0.000198	0.00218	CcSEcCtD
Etodolac—Rash maculo-papular—Doxorubicin—thyroid cancer	0.000197	0.00217	CcSEcCtD
Etodolac—Decreased appetite—Sorafenib—thyroid cancer	0.000197	0.00216	CcSEcCtD
Etodolac—Mouth ulceration—Doxorubicin—thyroid cancer	0.000196	0.00216	CcSEcCtD
Etodolac—Ecchymosis—Doxorubicin—thyroid cancer	0.000196	0.00216	CcSEcCtD
Etodolac—Bladder pain—Doxorubicin—thyroid cancer	0.000196	0.00216	CcSEcCtD
Etodolac—Fatigue—Sorafenib—thyroid cancer	0.000195	0.00215	CcSEcCtD
Etodolac—Photosensitivity—Epirubicin—thyroid cancer	0.000194	0.00213	CcSEcCtD
Etodolac—Pain—Sorafenib—thyroid cancer	0.000193	0.00213	CcSEcCtD
Etodolac—Constipation—Sorafenib—thyroid cancer	0.000193	0.00213	CcSEcCtD
Etodolac—Vascular purpura—Epirubicin—thyroid cancer	0.00019	0.00209	CcSEcCtD
Etodolac—Hepatic failure—Epirubicin—thyroid cancer	0.000189	0.00208	CcSEcCtD
Etodolac—Sepsis—Doxorubicin—thyroid cancer	0.000188	0.00207	CcSEcCtD
Etodolac—Cardiac failure congestive—Epirubicin—thyroid cancer	0.000188	0.00206	CcSEcCtD
Etodolac—Gastrointestinal pain—Sorafenib—thyroid cancer	0.000185	0.00203	CcSEcCtD
Etodolac—Lymphadenopathy—Doxorubicin—thyroid cancer	0.000184	0.00203	CcSEcCtD
Etodolac—Dermatitis exfoliative—Epirubicin—thyroid cancer	0.00018	0.00198	CcSEcCtD
Etodolac—Urticaria—Sorafenib—thyroid cancer	0.00018	0.00198	CcSEcCtD
Etodolac—Photosensitivity—Doxorubicin—thyroid cancer	0.000179	0.00197	CcSEcCtD
Etodolac—Abdominal pain—Sorafenib—thyroid cancer	0.000179	0.00197	CcSEcCtD
Etodolac—Body temperature increased—Sorafenib—thyroid cancer	0.000179	0.00197	CcSEcCtD
Etodolac—Renal impairment—Epirubicin—thyroid cancer	0.000179	0.00197	CcSEcCtD
Etodolac—Dermatitis bullous—Epirubicin—thyroid cancer	0.000178	0.00196	CcSEcCtD
Etodolac—Purpura—Epirubicin—thyroid cancer	0.000176	0.00194	CcSEcCtD
Etodolac—Vascular purpura—Doxorubicin—thyroid cancer	0.000176	0.00194	CcSEcCtD
Etodolac—Anaphylactoid reaction—Epirubicin—thyroid cancer	0.000176	0.00193	CcSEcCtD
Etodolac—Hepatic failure—Doxorubicin—thyroid cancer	0.000175	0.00193	CcSEcCtD
Etodolac—Cerebrovascular accident—Epirubicin—thyroid cancer	0.000174	0.00191	CcSEcCtD
Etodolac—Cardiac failure congestive—Doxorubicin—thyroid cancer	0.000174	0.00191	CcSEcCtD
Etodolac—Gastrointestinal haemorrhage—Epirubicin—thyroid cancer	0.00017	0.00187	CcSEcCtD
Etodolac—Dermatitis exfoliative—Doxorubicin—thyroid cancer	0.000167	0.00183	CcSEcCtD
Etodolac—Hypersensitivity—Sorafenib—thyroid cancer	0.000167	0.00183	CcSEcCtD
Etodolac—Renal impairment—Doxorubicin—thyroid cancer	0.000165	0.00182	CcSEcCtD
Etodolac—Dermatitis bullous—Doxorubicin—thyroid cancer	0.000165	0.00181	CcSEcCtD
Etodolac—Purpura—Doxorubicin—thyroid cancer	0.000163	0.0018	CcSEcCtD
Etodolac—Anaphylactoid reaction—Doxorubicin—thyroid cancer	0.000163	0.00179	CcSEcCtD
Etodolac—Asthenia—Sorafenib—thyroid cancer	0.000162	0.00179	CcSEcCtD
Etodolac—Cerebrovascular accident—Doxorubicin—thyroid cancer	0.000161	0.00177	CcSEcCtD
Etodolac—Pruritus—Sorafenib—thyroid cancer	0.00016	0.00176	CcSEcCtD
Etodolac—UGT1A3—NRF2 pathway—RXRA—thyroid cancer	0.000159	0.00442	CbGpPWpGaD
Etodolac—CYP2C9—Constitutive Androstane Receptor Pathway—RXRA—thyroid cancer	0.000159	0.00441	CbGpPWpGaD
Etodolac—PTGS1—Prostaglandin Synthesis and Regulation—PTGS2—thyroid cancer	0.000158	0.00438	CbGpPWpGaD
Etodolac—Gastrointestinal haemorrhage—Doxorubicin—thyroid cancer	0.000157	0.00173	CcSEcCtD
Etodolac—Abdominal pain upper—Epirubicin—thyroid cancer	0.000155	0.00171	CcSEcCtD
Etodolac—Diarrhoea—Sorafenib—thyroid cancer	0.000155	0.0017	CcSEcCtD
Etodolac—Toxic epidermal necrolysis—Epirubicin—thyroid cancer	0.000153	0.00168	CcSEcCtD
Etodolac—Gastritis—Epirubicin—thyroid cancer	0.000151	0.00166	CcSEcCtD
Etodolac—RXRA—NRF2 pathway—SLC5A5—thyroid cancer	0.00015	0.00417	CbGpPWpGaD
Etodolac—Dizziness—Sorafenib—thyroid cancer	0.00015	0.00165	CcSEcCtD
Etodolac—PTGS1—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.000148	0.00411	CbGpPWpGaD
Etodolac—Abdominal distension—Epirubicin—thyroid cancer	0.000148	0.00163	CcSEcCtD
Etodolac—Asthma—Epirubicin—thyroid cancer	0.000147	0.00162	CcSEcCtD
Etodolac—Eosinophilia—Epirubicin—thyroid cancer	0.000146	0.0016	CcSEcCtD
Etodolac—Pancreatitis—Epirubicin—thyroid cancer	0.000144	0.00159	CcSEcCtD
Etodolac—Vomiting—Sorafenib—thyroid cancer	0.000144	0.00158	CcSEcCtD
Etodolac—Abdominal pain upper—Doxorubicin—thyroid cancer	0.000144	0.00158	CcSEcCtD
Etodolac—Rash—Sorafenib—thyroid cancer	0.000143	0.00157	CcSEcCtD
Etodolac—Dermatitis—Sorafenib—thyroid cancer	0.000142	0.00157	CcSEcCtD
Etodolac—Toxic epidermal necrolysis—Doxorubicin—thyroid cancer	0.000142	0.00156	CcSEcCtD
Etodolac—Headache—Sorafenib—thyroid cancer	0.000142	0.00156	CcSEcCtD
Etodolac—Bronchitis—Epirubicin—thyroid cancer	0.000141	0.00156	CcSEcCtD
Etodolac—CYP2C9—Metapathway biotransformation—CHST14—thyroid cancer	0.00014	0.00389	CbGpPWpGaD
Etodolac—UGT1A3—Biological oxidations—RXRA—thyroid cancer	0.00014	0.00388	CbGpPWpGaD
Etodolac—Pancytopenia—Epirubicin—thyroid cancer	0.00014	0.00154	CcSEcCtD
Etodolac—Gastritis—Doxorubicin—thyroid cancer	0.000139	0.00153	CcSEcCtD
Etodolac—UGT1A9—PPARA activates gene expression—RXRA—thyroid cancer	0.000138	0.00383	CbGpPWpGaD
Etodolac—UGT1A3—NRF2 pathway—NRG1—thyroid cancer	0.000138	0.00382	CbGpPWpGaD
Etodolac—Neutropenia—Epirubicin—thyroid cancer	0.000137	0.00151	CcSEcCtD
Etodolac—Dysuria—Epirubicin—thyroid cancer	0.000137	0.00151	CcSEcCtD
Etodolac—Abdominal distension—Doxorubicin—thyroid cancer	0.000137	0.00151	CcSEcCtD
Etodolac—Asthma—Doxorubicin—thyroid cancer	0.000136	0.0015	CcSEcCtD
Etodolac—Pollakiuria—Epirubicin—thyroid cancer	0.000136	0.00149	CcSEcCtD
Etodolac—UGT2B7—NRF2 pathway—RXRA—thyroid cancer	0.000135	0.00376	CbGpPWpGaD
Etodolac—UGT1A9—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—RXRA—thyroid cancer	0.000135	0.00375	CbGpPWpGaD
Etodolac—Eosinophilia—Doxorubicin—thyroid cancer	0.000135	0.00148	CcSEcCtD
Etodolac—Nausea—Sorafenib—thyroid cancer	0.000134	0.00148	CcSEcCtD
Etodolac—Photosensitivity reaction—Epirubicin—thyroid cancer	0.000134	0.00148	CcSEcCtD
Etodolac—Pancreatitis—Doxorubicin—thyroid cancer	0.000133	0.00147	CcSEcCtD
Etodolac—PTGS2—Spinal Cord Injury—LGALS3—thyroid cancer	0.000133	0.00369	CbGpPWpGaD
Etodolac—RXRA—Transcriptional regulation of white adipocyte differentiation—PPARG—thyroid cancer	0.000133	0.00369	CbGpPWpGaD
Etodolac—Hyperglycaemia—Epirubicin—thyroid cancer	0.000133	0.00146	CcSEcCtD
Etodolac—Pneumonia—Epirubicin—thyroid cancer	0.000132	0.00145	CcSEcCtD
Etodolac—UGT1A9—NRF2 pathway—SLC5A5—thyroid cancer	0.000131	0.00363	CbGpPWpGaD
Etodolac—Bronchitis—Doxorubicin—thyroid cancer	0.000131	0.00144	CcSEcCtD
Etodolac—Stevens-Johnson syndrome—Epirubicin—thyroid cancer	0.00013	0.00143	CcSEcCtD
Etodolac—Pancytopenia—Doxorubicin—thyroid cancer	0.000129	0.00142	CcSEcCtD
Etodolac—Renal failure—Epirubicin—thyroid cancer	0.000129	0.00142	CcSEcCtD
Etodolac—Stomatitis—Epirubicin—thyroid cancer	0.000128	0.00141	CcSEcCtD
Etodolac—Jaundice—Epirubicin—thyroid cancer	0.000128	0.00141	CcSEcCtD
Etodolac—Conjunctivitis—Epirubicin—thyroid cancer	0.000127	0.0014	CcSEcCtD
Etodolac—Neutropenia—Doxorubicin—thyroid cancer	0.000127	0.0014	CcSEcCtD
Etodolac—Dysuria—Doxorubicin—thyroid cancer	0.000127	0.0014	CcSEcCtD
Etodolac—Sweating—Epirubicin—thyroid cancer	0.000126	0.00138	CcSEcCtD
Etodolac—Pollakiuria—Doxorubicin—thyroid cancer	0.000126	0.00138	CcSEcCtD
Etodolac—Haematuria—Epirubicin—thyroid cancer	0.000125	0.00137	CcSEcCtD
Etodolac—Photosensitivity reaction—Doxorubicin—thyroid cancer	0.000124	0.00137	CcSEcCtD
Etodolac—Sinusitis—Epirubicin—thyroid cancer	0.000123	0.00135	CcSEcCtD
Etodolac—Hyperglycaemia—Doxorubicin—thyroid cancer	0.000123	0.00135	CcSEcCtD
Etodolac—Agranulocytosis—Epirubicin—thyroid cancer	0.000122	0.00135	CcSEcCtD
Etodolac—Pneumonia—Doxorubicin—thyroid cancer	0.000122	0.00134	CcSEcCtD
Etodolac—Stevens-Johnson syndrome—Doxorubicin—thyroid cancer	0.00012	0.00132	CcSEcCtD
Etodolac—Renal failure—Doxorubicin—thyroid cancer	0.000119	0.00131	CcSEcCtD
Etodolac—RXRA—Generic Transcription Pathway—THRB—thyroid cancer	0.000119	0.0033	CbGpPWpGaD
Etodolac—UGT2B7—Biological oxidations—RXRA—thyroid cancer	0.000119	0.0033	CbGpPWpGaD
Etodolac—Haemoglobin—Epirubicin—thyroid cancer	0.000118	0.0013	CcSEcCtD
Etodolac—Stomatitis—Doxorubicin—thyroid cancer	0.000118	0.0013	CcSEcCtD
Etodolac—Jaundice—Doxorubicin—thyroid cancer	0.000118	0.0013	CcSEcCtD
Etodolac—Rhinitis—Epirubicin—thyroid cancer	0.000118	0.0013	CcSEcCtD
Etodolac—Conjunctivitis—Doxorubicin—thyroid cancer	0.000118	0.0013	CcSEcCtD
Etodolac—RXRA—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.000118	0.00327	CbGpPWpGaD
Etodolac—Haemorrhage—Epirubicin—thyroid cancer	0.000118	0.00129	CcSEcCtD
Etodolac—Hepatitis—Epirubicin—thyroid cancer	0.000118	0.00129	CcSEcCtD
Etodolac—UGT2B7—NRF2 pathway—NRG1—thyroid cancer	0.000117	0.00325	CbGpPWpGaD
Etodolac—Pharyngitis—Epirubicin—thyroid cancer	0.000117	0.00128	CcSEcCtD
Etodolac—Sweating—Doxorubicin—thyroid cancer	0.000116	0.00128	CcSEcCtD
Etodolac—Haematuria—Doxorubicin—thyroid cancer	0.000116	0.00127	CcSEcCtD
Etodolac—Sinusitis—Doxorubicin—thyroid cancer	0.000114	0.00125	CcSEcCtD
Etodolac—Visual impairment—Epirubicin—thyroid cancer	0.000113	0.00125	CcSEcCtD
Etodolac—Agranulocytosis—Doxorubicin—thyroid cancer	0.000113	0.00124	CcSEcCtD
Etodolac—RXRA—Retinoic acid receptors-mediated signaling—AKT1—thyroid cancer	0.000112	0.0031	CbGpPWpGaD
Etodolac—Erythema multiforme—Epirubicin—thyroid cancer	0.000111	0.00122	CcSEcCtD
Etodolac—SLC22A6—SLC-mediated transmembrane transport—CP—thyroid cancer	0.000111	0.00308	CbGpPWpGaD
Etodolac—SLC22A6—SLC-mediated transmembrane transport—TPR—thyroid cancer	0.000111	0.00308	CbGpPWpGaD
Etodolac—UGT1A9—NRF2 pathway—RXRA—thyroid cancer	0.00011	0.00305	CbGpPWpGaD
Etodolac—Tinnitus—Epirubicin—thyroid cancer	0.00011	0.00121	CcSEcCtD
Etodolac—Haemoglobin—Doxorubicin—thyroid cancer	0.000109	0.0012	CcSEcCtD
Etodolac—RXRA—NRF2 pathway—NRG1—thyroid cancer	0.000109	0.00303	CbGpPWpGaD
Etodolac—Flushing—Epirubicin—thyroid cancer	0.000109	0.0012	CcSEcCtD
Etodolac—Rhinitis—Doxorubicin—thyroid cancer	0.000109	0.0012	CcSEcCtD
Etodolac—Haemorrhage—Doxorubicin—thyroid cancer	0.000109	0.0012	CcSEcCtD
Etodolac—Hepatitis—Doxorubicin—thyroid cancer	0.000109	0.0012	CcSEcCtD
Etodolac—Pharyngitis—Doxorubicin—thyroid cancer	0.000108	0.00119	CcSEcCtD
Etodolac—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—PPARG—thyroid cancer	0.000106	0.00294	CbGpPWpGaD
Etodolac—Chills—Epirubicin—thyroid cancer	0.000106	0.00116	CcSEcCtD
Etodolac—Arrhythmia—Epirubicin—thyroid cancer	0.000105	0.00116	CcSEcCtD
Etodolac—PTGS1—Arachidonic acid metabolism—PTGS2—thyroid cancer	0.000105	0.00291	CbGpPWpGaD
Etodolac—Visual impairment—Doxorubicin—thyroid cancer	0.000105	0.00115	CcSEcCtD
Etodolac—Alopecia—Epirubicin—thyroid cancer	0.000104	0.00114	CcSEcCtD
Etodolac—RXRA—Adipogenesis—HIF1A—thyroid cancer	0.000103	0.00286	CbGpPWpGaD
Etodolac—Erythema multiforme—Doxorubicin—thyroid cancer	0.000103	0.00113	CcSEcCtD
Etodolac—UGT1A3—Metabolism—MINPP1—thyroid cancer	0.000103	0.00285	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.000103	0.00285	CbGpPWpGaD
Etodolac—Tinnitus—Doxorubicin—thyroid cancer	0.000102	0.00112	CcSEcCtD
Etodolac—Flushing—Doxorubicin—thyroid cancer	0.000101	0.00111	CcSEcCtD
Etodolac—Flatulence—Epirubicin—thyroid cancer	0.000101	0.00111	CcSEcCtD
Etodolac—Tension—Epirubicin—thyroid cancer	0.000101	0.00111	CcSEcCtD
Etodolac—Dysgeusia—Epirubicin—thyroid cancer	0.0001	0.0011	CcSEcCtD
Etodolac—RXRA—PPARA activates gene expression—PPARG—thyroid cancer	0.0001	0.00277	CbGpPWpGaD
Etodolac—Nervousness—Epirubicin—thyroid cancer	9.95e-05	0.00109	CcSEcCtD
Etodolac—RXRA—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—PPARG—thyroid cancer	9.79e-05	0.00272	CbGpPWpGaD
Etodolac—Chills—Doxorubicin—thyroid cancer	9.77e-05	0.00107	CcSEcCtD
Etodolac—Arrhythmia—Doxorubicin—thyroid cancer	9.73e-05	0.00107	CcSEcCtD
Etodolac—UGT1A9—Biological oxidations—RXRA—thyroid cancer	9.65e-05	0.00268	CbGpPWpGaD
Etodolac—Vision blurred—Epirubicin—thyroid cancer	9.65e-05	0.00106	CcSEcCtD
Etodolac—Alopecia—Doxorubicin—thyroid cancer	9.62e-05	0.00106	CcSEcCtD
Etodolac—CYP2C9—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	9.61e-05	0.00266	CbGpPWpGaD
Etodolac—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—thyroid cancer	9.55e-05	0.00265	CbGpPWpGaD
Etodolac—UGT1A9—NRF2 pathway—NRG1—thyroid cancer	9.52e-05	0.00264	CbGpPWpGaD
Etodolac—Ill-defined disorder—Epirubicin—thyroid cancer	9.5e-05	0.00105	CcSEcCtD
Etodolac—Anaemia—Epirubicin—thyroid cancer	9.47e-05	0.00104	CcSEcCtD
Etodolac—Flatulence—Doxorubicin—thyroid cancer	9.34e-05	0.00103	CcSEcCtD
Etodolac—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—RXRA—thyroid cancer	9.31e-05	0.00258	CbGpPWpGaD
Etodolac—Tension—Doxorubicin—thyroid cancer	9.3e-05	0.00102	CcSEcCtD
Etodolac—Dysgeusia—Doxorubicin—thyroid cancer	9.28e-05	0.00102	CcSEcCtD
Etodolac—Malaise—Epirubicin—thyroid cancer	9.24e-05	0.00102	CcSEcCtD
Etodolac—Nervousness—Doxorubicin—thyroid cancer	9.2e-05	0.00101	CcSEcCtD
Etodolac—Vertigo—Epirubicin—thyroid cancer	9.2e-05	0.00101	CcSEcCtD
Etodolac—Syncope—Epirubicin—thyroid cancer	9.18e-05	0.00101	CcSEcCtD
Etodolac—Leukopenia—Epirubicin—thyroid cancer	9.17e-05	0.00101	CcSEcCtD
Etodolac—RXRA—a6b1 and a6b4 Integrin signaling—HRAS—thyroid cancer	9.16e-05	0.00254	CbGpPWpGaD
Etodolac—PTGS2—Spinal Cord Injury—CDK1—thyroid cancer	9.1e-05	0.00252	CbGpPWpGaD
Etodolac—Palpitations—Epirubicin—thyroid cancer	9.05e-05	0.000996	CcSEcCtD
Etodolac—Loss of consciousness—Epirubicin—thyroid cancer	9e-05	0.00099	CcSEcCtD
Etodolac—Vision blurred—Doxorubicin—thyroid cancer	8.93e-05	0.000983	CcSEcCtD
Etodolac—Convulsion—Epirubicin—thyroid cancer	8.87e-05	0.000976	CcSEcCtD
Etodolac—Hypertension—Epirubicin—thyroid cancer	8.84e-05	0.000973	CcSEcCtD
Etodolac—Ill-defined disorder—Doxorubicin—thyroid cancer	8.79e-05	0.000967	CcSEcCtD
Etodolac—Anaemia—Doxorubicin—thyroid cancer	8.76e-05	0.000964	CcSEcCtD
Etodolac—RXRA—Adipogenesis—PPARG—thyroid cancer	8.75e-05	0.00243	CbGpPWpGaD
Etodolac—UGT1A3—Metabolism—NDUFA13—thyroid cancer	8.73e-05	0.00242	CbGpPWpGaD
Etodolac—UGT2B7—Metabolism—MINPP1—thyroid cancer	8.73e-05	0.00242	CbGpPWpGaD
Etodolac—Arthralgia—Epirubicin—thyroid cancer	8.72e-05	0.000959	CcSEcCtD
Etodolac—Myalgia—Epirubicin—thyroid cancer	8.72e-05	0.000959	CcSEcCtD
Etodolac—UGT1A9—PPARA activates gene expression—PPARG—thyroid cancer	8.72e-05	0.00242	CbGpPWpGaD
Etodolac—Anxiety—Epirubicin—thyroid cancer	8.69e-05	0.000956	CcSEcCtD
Etodolac—Discomfort—Epirubicin—thyroid cancer	8.62e-05	0.000948	CcSEcCtD
Etodolac—Malaise—Doxorubicin—thyroid cancer	8.55e-05	0.00094	CcSEcCtD
Etodolac—UGT1A9—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—PPARG—thyroid cancer	8.53e-05	0.00237	CbGpPWpGaD
Etodolac—Dry mouth—Epirubicin—thyroid cancer	8.53e-05	0.000938	CcSEcCtD
Etodolac—Vertigo—Doxorubicin—thyroid cancer	8.51e-05	0.000937	CcSEcCtD
Etodolac—Syncope—Doxorubicin—thyroid cancer	8.5e-05	0.000935	CcSEcCtD
Etodolac—Leukopenia—Doxorubicin—thyroid cancer	8.48e-05	0.000933	CcSEcCtD
Etodolac—Confusional state—Epirubicin—thyroid cancer	8.43e-05	0.000927	CcSEcCtD
Etodolac—Palpitations—Doxorubicin—thyroid cancer	8.37e-05	0.000921	CcSEcCtD
Etodolac—PTGS1—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	8.37e-05	0.00232	CbGpPWpGaD
Etodolac—Oedema—Epirubicin—thyroid cancer	8.36e-05	0.00092	CcSEcCtD
Etodolac—Anaphylactic shock—Epirubicin—thyroid cancer	8.36e-05	0.00092	CcSEcCtD
Etodolac—Loss of consciousness—Doxorubicin—thyroid cancer	8.33e-05	0.000916	CcSEcCtD
Etodolac—SLC22A6—SLC-mediated transmembrane transport—SLC5A5—thyroid cancer	8.32e-05	0.00231	CbGpPWpGaD
Etodolac—Infection—Epirubicin—thyroid cancer	8.3e-05	0.000914	CcSEcCtD
Etodolac—Shock—Epirubicin—thyroid cancer	8.22e-05	0.000905	CcSEcCtD
Etodolac—Convulsion—Doxorubicin—thyroid cancer	8.21e-05	0.000903	CcSEcCtD
Etodolac—UGT1A3—Metabolism—CHST14—thyroid cancer	8.21e-05	0.00228	CbGpPWpGaD
Etodolac—Thrombocytopenia—Epirubicin—thyroid cancer	8.18e-05	0.0009	CcSEcCtD
Etodolac—Hypertension—Doxorubicin—thyroid cancer	8.18e-05	0.0009	CcSEcCtD
Etodolac—Tachycardia—Epirubicin—thyroid cancer	8.16e-05	0.000897	CcSEcCtD
Etodolac—RXRA—Metabolism—MINPP1—thyroid cancer	8.14e-05	0.00226	CbGpPWpGaD
Etodolac—RXRA—a6b1 and a6b4 Integrin signaling—AKT1—thyroid cancer	8.09e-05	0.00224	CbGpPWpGaD
Etodolac—Hyperhidrosis—Epirubicin—thyroid cancer	8.08e-05	0.000889	CcSEcCtD
Etodolac—Myalgia—Doxorubicin—thyroid cancer	8.07e-05	0.000888	CcSEcCtD
Etodolac—Arthralgia—Doxorubicin—thyroid cancer	8.07e-05	0.000888	CcSEcCtD
Etodolac—Anxiety—Doxorubicin—thyroid cancer	8.04e-05	0.000884	CcSEcCtD
Etodolac—Discomfort—Doxorubicin—thyroid cancer	7.97e-05	0.000877	CcSEcCtD
Etodolac—Anorexia—Epirubicin—thyroid cancer	7.97e-05	0.000877	CcSEcCtD
Etodolac—RXRA—Gene Expression—TRIM33—thyroid cancer	7.93e-05	0.0022	CbGpPWpGaD
Etodolac—Dry mouth—Doxorubicin—thyroid cancer	7.89e-05	0.000868	CcSEcCtD
Etodolac—PTGS1—Biological oxidations—RXRA—thyroid cancer	7.87e-05	0.00218	CbGpPWpGaD
Etodolac—Hypotension—Epirubicin—thyroid cancer	7.81e-05	0.000859	CcSEcCtD
Etodolac—Confusional state—Doxorubicin—thyroid cancer	7.8e-05	0.000858	CcSEcCtD
Etodolac—CYP2C9—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	7.79e-05	0.00216	CbGpPWpGaD
Etodolac—Anaphylactic shock—Doxorubicin—thyroid cancer	7.73e-05	0.000851	CcSEcCtD
Etodolac—Oedema—Doxorubicin—thyroid cancer	7.73e-05	0.000851	CcSEcCtD
Etodolac—Infection—Doxorubicin—thyroid cancer	7.68e-05	0.000845	CcSEcCtD
Etodolac—Musculoskeletal discomfort—Epirubicin—thyroid cancer	7.62e-05	0.000838	CcSEcCtD
Etodolac—Shock—Doxorubicin—thyroid cancer	7.61e-05	0.000837	CcSEcCtD
Etodolac—Thrombocytopenia—Doxorubicin—thyroid cancer	7.57e-05	0.000833	CcSEcCtD
Etodolac—RXRA—Generic Transcription Pathway—MEN1—thyroid cancer	7.57e-05	0.0021	CbGpPWpGaD
Etodolac—Insomnia—Epirubicin—thyroid cancer	7.56e-05	0.000832	CcSEcCtD
Etodolac—Tachycardia—Doxorubicin—thyroid cancer	7.55e-05	0.00083	CcSEcCtD
Etodolac—Paraesthesia—Epirubicin—thyroid cancer	7.51e-05	0.000826	CcSEcCtD
Etodolac—Hyperhidrosis—Doxorubicin—thyroid cancer	7.48e-05	0.000823	CcSEcCtD
Etodolac—Dyspnoea—Epirubicin—thyroid cancer	7.45e-05	0.00082	CcSEcCtD
Etodolac—Somnolence—Epirubicin—thyroid cancer	7.43e-05	0.000817	CcSEcCtD
Etodolac—UGT2B7—Metabolism—NDUFA13—thyroid cancer	7.42e-05	0.00206	CbGpPWpGaD
Etodolac—Anorexia—Doxorubicin—thyroid cancer	7.37e-05	0.000811	CcSEcCtD
Etodolac—Dyspepsia—Epirubicin—thyroid cancer	7.36e-05	0.000809	CcSEcCtD
Etodolac—Decreased appetite—Epirubicin—thyroid cancer	7.27e-05	0.000799	CcSEcCtD
Etodolac—Hypotension—Doxorubicin—thyroid cancer	7.23e-05	0.000795	CcSEcCtD
Etodolac—Fatigue—Epirubicin—thyroid cancer	7.21e-05	0.000793	CcSEcCtD
Etodolac—Constipation—Epirubicin—thyroid cancer	7.15e-05	0.000786	CcSEcCtD
Etodolac—Pain—Epirubicin—thyroid cancer	7.15e-05	0.000786	CcSEcCtD
Etodolac—UGT1A9—Metabolism—MINPP1—thyroid cancer	7.09e-05	0.00197	CbGpPWpGaD
Etodolac—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	7.05e-05	0.000775	CcSEcCtD
Etodolac—Insomnia—Doxorubicin—thyroid cancer	7e-05	0.00077	CcSEcCtD
Etodolac—UGT2B7—Metabolism—CHST14—thyroid cancer	6.98e-05	0.00194	CbGpPWpGaD
Etodolac—Paraesthesia—Doxorubicin—thyroid cancer	6.94e-05	0.000764	CcSEcCtD
Etodolac—PTGS2—Aryl Hydrocarbon Receptor—NRAS—thyroid cancer	6.93e-05	0.00192	CbGpPWpGaD
Etodolac—RXRA—Metabolism—NDUFA13—thyroid cancer	6.92e-05	0.00192	CbGpPWpGaD
Etodolac—Dyspnoea—Doxorubicin—thyroid cancer	6.9e-05	0.000759	CcSEcCtD
Etodolac—Feeling abnormal—Epirubicin—thyroid cancer	6.89e-05	0.000758	CcSEcCtD
Etodolac—Somnolence—Doxorubicin—thyroid cancer	6.88e-05	0.000756	CcSEcCtD
Etodolac—Gastrointestinal pain—Epirubicin—thyroid cancer	6.84e-05	0.000752	CcSEcCtD
Etodolac—Dyspepsia—Doxorubicin—thyroid cancer	6.81e-05	0.000749	CcSEcCtD
Etodolac—RXRA—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—thyroid cancer	6.75e-05	0.00187	CbGpPWpGaD
Etodolac—Decreased appetite—Doxorubicin—thyroid cancer	6.72e-05	0.00074	CcSEcCtD
Etodolac—PTGS1—Selenium Micronutrient Network—PTGS2—thyroid cancer	6.68e-05	0.00185	CbGpPWpGaD
Etodolac—Fatigue—Doxorubicin—thyroid cancer	6.67e-05	0.000734	CcSEcCtD
Etodolac—PTGS2—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	6.64e-05	0.00184	CbGpPWpGaD
Etodolac—Urticaria—Epirubicin—thyroid cancer	6.64e-05	0.000731	CcSEcCtD
Etodolac—UGT1A3—Metabolism—HPGD—thyroid cancer	6.61e-05	0.00183	CbGpPWpGaD
Etodolac—Constipation—Doxorubicin—thyroid cancer	6.61e-05	0.000728	CcSEcCtD
Etodolac—Pain—Doxorubicin—thyroid cancer	6.61e-05	0.000728	CcSEcCtD
Etodolac—Abdominal pain—Epirubicin—thyroid cancer	6.61e-05	0.000727	CcSEcCtD
Etodolac—Body temperature increased—Epirubicin—thyroid cancer	6.61e-05	0.000727	CcSEcCtD
Etodolac—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—thyroid cancer	6.6e-05	0.00183	CbGpPWpGaD
Etodolac—RXRA—Metabolism—CHST14—thyroid cancer	6.51e-05	0.00181	CbGpPWpGaD
Etodolac—RXRA—Transmembrane transport of small molecules—TPR—thyroid cancer	6.43e-05	0.00178	CbGpPWpGaD
Etodolac—RXRA—Transmembrane transport of small molecules—CP—thyroid cancer	6.43e-05	0.00178	CbGpPWpGaD
Etodolac—Feeling abnormal—Doxorubicin—thyroid cancer	6.37e-05	0.000701	CcSEcCtD
Etodolac—RXRA—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	6.33e-05	0.00176	CbGpPWpGaD
Etodolac—Gastrointestinal pain—Doxorubicin—thyroid cancer	6.32e-05	0.000696	CcSEcCtD
Etodolac—Hypersensitivity—Epirubicin—thyroid cancer	6.16e-05	0.000677	CcSEcCtD
Etodolac—Urticaria—Doxorubicin—thyroid cancer	6.14e-05	0.000676	CcSEcCtD
Etodolac—Abdominal pain—Doxorubicin—thyroid cancer	6.11e-05	0.000673	CcSEcCtD
Etodolac—Body temperature increased—Doxorubicin—thyroid cancer	6.11e-05	0.000673	CcSEcCtD
Etodolac—UGT1A9—Metabolism—NDUFA13—thyroid cancer	6.03e-05	0.00167	CbGpPWpGaD
Etodolac—Asthenia—Epirubicin—thyroid cancer	6e-05	0.00066	CcSEcCtD
Etodolac—PTGS2—Aryl Hydrocarbon Receptor—KRAS—thyroid cancer	5.97e-05	0.00166	CbGpPWpGaD
Etodolac—Pruritus—Epirubicin—thyroid cancer	5.91e-05	0.000651	CcSEcCtD
Etodolac—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—thyroid cancer	5.88e-05	0.00163	CbGpPWpGaD
Etodolac—PTGS1—Metabolism—MINPP1—thyroid cancer	5.78e-05	0.0016	CbGpPWpGaD
Etodolac—ALB—SLC-mediated transmembrane transport—TPR—thyroid cancer	5.77e-05	0.0016	CbGpPWpGaD
Etodolac—ALB—SLC-mediated transmembrane transport—CP—thyroid cancer	5.77e-05	0.0016	CbGpPWpGaD
Etodolac—PTGS2—Integrated Pancreatic Cancer Pathway—RXRA—thyroid cancer	5.74e-05	0.00159	CbGpPWpGaD
Etodolac—RXRA—Gene Expression—THRB—thyroid cancer	5.74e-05	0.00159	CbGpPWpGaD
Etodolac—Diarrhoea—Epirubicin—thyroid cancer	5.72e-05	0.000629	CcSEcCtD
Etodolac—Hypersensitivity—Doxorubicin—thyroid cancer	5.7e-05	0.000627	CcSEcCtD
Etodolac—UGT1A9—Metabolism—CHST14—thyroid cancer	5.67e-05	0.00157	CbGpPWpGaD
Etodolac—SLC22A6—Transmembrane transport of small molecules—TPR—thyroid cancer	5.64e-05	0.00157	CbGpPWpGaD
Etodolac—SLC22A6—Transmembrane transport of small molecules—CP—thyroid cancer	5.64e-05	0.00157	CbGpPWpGaD
Etodolac—UGT2B7—Metabolism—HPGD—thyroid cancer	5.62e-05	0.00156	CbGpPWpGaD
Etodolac—SLC22A6—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	5.55e-05	0.00154	CbGpPWpGaD
Etodolac—Asthenia—Doxorubicin—thyroid cancer	5.55e-05	0.00061	CcSEcCtD
Etodolac—Dizziness—Epirubicin—thyroid cancer	5.53e-05	0.000608	CcSEcCtD
Etodolac—CYP2C9—Arachidonic acid metabolism—PTGS2—thyroid cancer	5.52e-05	0.00153	CbGpPWpGaD
Etodolac—Pruritus—Doxorubicin—thyroid cancer	5.47e-05	0.000602	CcSEcCtD
Etodolac—ALB—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	5.37e-05	0.00149	CbGpPWpGaD
Etodolac—Vomiting—Epirubicin—thyroid cancer	5.31e-05	0.000585	CcSEcCtD
Etodolac—Diarrhoea—Doxorubicin—thyroid cancer	5.29e-05	0.000582	CcSEcCtD
Etodolac—Rash—Epirubicin—thyroid cancer	5.27e-05	0.00058	CcSEcCtD
Etodolac—Dermatitis—Epirubicin—thyroid cancer	5.27e-05	0.000579	CcSEcCtD
Etodolac—RXRA—Metabolism—HPGD—thyroid cancer	5.25e-05	0.00146	CbGpPWpGaD
Etodolac—Headache—Epirubicin—thyroid cancer	5.24e-05	0.000576	CcSEcCtD
Etodolac—RXRA—Developmental Biology—CDK1—thyroid cancer	5.13e-05	0.00142	CbGpPWpGaD
Etodolac—Dizziness—Doxorubicin—thyroid cancer	5.11e-05	0.000563	CcSEcCtD
Etodolac—PTGS2—Aryl Hydrocarbon Receptor—HRAS—thyroid cancer	5.07e-05	0.00141	CbGpPWpGaD
Etodolac—RXRA—Integrated Pancreatic Cancer Pathway—PTGS2—thyroid cancer	5.06e-05	0.0014	CbGpPWpGaD
Etodolac—PTGS2—C-MYB transcription factor network—CCND1—thyroid cancer	4.97e-05	0.00138	CbGpPWpGaD
Etodolac—Nausea—Epirubicin—thyroid cancer	4.97e-05	0.000546	CcSEcCtD
Etodolac—Vomiting—Doxorubicin—thyroid cancer	4.92e-05	0.000541	CcSEcCtD
Etodolac—PTGS1—Metabolism—NDUFA13—thyroid cancer	4.92e-05	0.00136	CbGpPWpGaD
Etodolac—Rash—Doxorubicin—thyroid cancer	4.88e-05	0.000536	CcSEcCtD
Etodolac—Dermatitis—Doxorubicin—thyroid cancer	4.87e-05	0.000536	CcSEcCtD
Etodolac—Headache—Doxorubicin—thyroid cancer	4.85e-05	0.000533	CcSEcCtD
Etodolac—RXRA—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	4.82e-05	0.00134	CbGpPWpGaD
Etodolac—PTGS2—Disease—TRIM24—thyroid cancer	4.66e-05	0.00129	CbGpPWpGaD
Etodolac—PTGS1—Metabolism—CHST14—thyroid cancer	4.62e-05	0.00128	CbGpPWpGaD
Etodolac—Nausea—Doxorubicin—thyroid cancer	4.59e-05	0.000505	CcSEcCtD
Etodolac—PTGS2—Metabolism—MINPP1—thyroid cancer	4.59e-05	0.00127	CbGpPWpGaD
Etodolac—RXRA—Integrated Pancreatic Cancer Pathway—CCND1—thyroid cancer	4.57e-05	0.00127	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism—HPGD—thyroid cancer	4.57e-05	0.00127	CbGpPWpGaD
Etodolac—RXRA—Integrated Pancreatic Cancer Pathway—PTEN—thyroid cancer	4.41e-05	0.00122	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	4.4e-05	0.00122	CbGpPWpGaD
Etodolac—PTGS2—Disease—CHST14—thyroid cancer	4.38e-05	0.00122	CbGpPWpGaD
Etodolac—ALB—SLC-mediated transmembrane transport—SLC5A5—thyroid cancer	4.32e-05	0.0012	CbGpPWpGaD
Etodolac—ALB—Selenium Micronutrient Network—PTGS2—thyroid cancer	4.29e-05	0.00119	CbGpPWpGaD
Etodolac—PTGS2—C-MYB transcription factor network—NRAS—thyroid cancer	4.28e-05	0.00119	CbGpPWpGaD
Etodolac—SLC22A6—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	4.23e-05	0.00117	CbGpPWpGaD
Etodolac—PTGS2—Disease—TRIM33—thyroid cancer	4.15e-05	0.00115	CbGpPWpGaD
Etodolac—CYP2C9—Biological oxidations—RXRA—thyroid cancer	4.14e-05	0.00115	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—NDUFA13—thyroid cancer	3.9e-05	0.00108	CbGpPWpGaD
Etodolac—RXRA—Gene Expression—TPR—thyroid cancer	3.87e-05	0.00107	CbGpPWpGaD
Etodolac—UGT1A3—Metabolism—TPR—thyroid cancer	3.8e-05	0.00105	CbGpPWpGaD
Etodolac—PTGS2—Spinal Cord Injury—CCND1—thyroid cancer	3.79e-05	0.00105	CbGpPWpGaD
Etodolac—ALB—FOXA2 and FOXA3 transcription factor networks—AKT1—thyroid cancer	3.76e-05	0.00104	CbGpPWpGaD
Etodolac—UGT1A3—Metabolism—PRKAR1A—thyroid cancer	3.74e-05	0.00104	CbGpPWpGaD
Etodolac—PTGS1—Metabolism—HPGD—thyroid cancer	3.73e-05	0.00103	CbGpPWpGaD
Etodolac—ALB—Metabolism—MINPP1—thyroid cancer	3.71e-05	0.00103	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	3.71e-05	0.00103	CbGpPWpGaD
Etodolac—PTGS2—C-MYB transcription factor network—KRAS—thyroid cancer	3.69e-05	0.00102	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—CHST14—thyroid cancer	3.67e-05	0.00102	CbGpPWpGaD
Etodolac—RXRA—Gene Expression—MEN1—thyroid cancer	3.64e-05	0.00101	CbGpPWpGaD
Etodolac—SLC22A6—Transmembrane transport of small molecules—RXRA—thyroid cancer	3.55e-05	0.000985	CbGpPWpGaD
Etodolac—RXRA—Integrated Pancreatic Cancer Pathway—KRAS—thyroid cancer	3.39e-05	0.00094	CbGpPWpGaD
Etodolac—ALB—Hemostasis—PRKAR1A—thyroid cancer	3.33e-05	0.000925	CbGpPWpGaD
Etodolac—UGT2B7—Metabolism—TPR—thyroid cancer	3.23e-05	0.000896	CbGpPWpGaD
Etodolac—ALB—Folate Metabolism—TP53—thyroid cancer	3.21e-05	0.000892	CbGpPWpGaD
Etodolac—RXRA—Generic Transcription Pathway—PPARG—thyroid cancer	3.2e-05	0.000886	CbGpPWpGaD
Etodolac—UGT2B7—Metabolism—PRKAR1A—thyroid cancer	3.18e-05	0.000881	CbGpPWpGaD
Etodolac—ALB—Metabolism—NDUFA13—thyroid cancer	3.16e-05	0.000876	CbGpPWpGaD
Etodolac—PTGS2—C-MYB transcription factor network—HRAS—thyroid cancer	3.13e-05	0.000869	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—MINPP1—thyroid cancer	3.04e-05	0.000843	CbGpPWpGaD
Etodolac—PTGS1—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	3.02e-05	0.000838	CbGpPWpGaD
Etodolac—RXRA—Metabolism—TPR—thyroid cancer	3.01e-05	0.000836	CbGpPWpGaD
Etodolac—RXRA—Integrated Pancreatic Cancer Pathway—TP53—thyroid cancer	3.01e-05	0.000836	CbGpPWpGaD
Etodolac—RXRA—Developmental Biology—PPARG—thyroid cancer	3.01e-05	0.000834	CbGpPWpGaD
Etodolac—ALB—Metabolism—CHST14—thyroid cancer	2.97e-05	0.000823	CbGpPWpGaD
Etodolac—RXRA—Metabolism—PRKAR1A—thyroid cancer	2.96e-05	0.000822	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—HPGD—thyroid cancer	2.96e-05	0.00082	CbGpPWpGaD
Etodolac—ALB—Transmembrane transport of small molecules—TPR—thyroid cancer	2.93e-05	0.000814	CbGpPWpGaD
Etodolac—ALB—Transmembrane transport of small molecules—CP—thyroid cancer	2.93e-05	0.000814	CbGpPWpGaD
Etodolac—ALB—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	2.89e-05	0.000801	CbGpPWpGaD
Etodolac—UGT1A3—Metabolism—SLC5A5—thyroid cancer	2.84e-05	0.000789	CbGpPWpGaD
Etodolac—PTGS2—Disease—TCF7L1—thyroid cancer	2.77e-05	0.000769	CbGpPWpGaD
Etodolac—RXRA—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	2.69e-05	0.000745	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism—TPR—thyroid cancer	2.62e-05	0.000728	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—NDUFA13—thyroid cancer	2.58e-05	0.000717	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism—PRKAR1A—thyroid cancer	2.58e-05	0.000716	CbGpPWpGaD
Etodolac—PTGS2—Integrated Pancreatic Cancer Pathway—CCND1—thyroid cancer	2.58e-05	0.000715	CbGpPWpGaD
Etodolac—RXRA—Integrated Pancreatic Cancer Pathway—AKT1—thyroid cancer	2.54e-05	0.000706	CbGpPWpGaD
Etodolac—PTGS2—Spinal Cord Injury—TP53—thyroid cancer	2.5e-05	0.000692	CbGpPWpGaD
Etodolac—PTGS2—Integrated Pancreatic Cancer Pathway—PTEN—thyroid cancer	2.49e-05	0.00069	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—CHST14—thyroid cancer	2.43e-05	0.000674	CbGpPWpGaD
Etodolac—UGT2B7—Metabolism—SLC5A5—thyroid cancer	2.42e-05	0.000671	CbGpPWpGaD
Etodolac—PTGS2—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	2.4e-05	0.000665	CbGpPWpGaD
Etodolac—ALB—Metabolism—HPGD—thyroid cancer	2.39e-05	0.000664	CbGpPWpGaD
Etodolac—UGT1A3—Metabolism—RXRA—thyroid cancer	2.39e-05	0.000663	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	2.34e-05	0.000649	CbGpPWpGaD
Etodolac—RXRA—Metabolism—SLC5A5—thyroid cancer	2.26e-05	0.000626	CbGpPWpGaD
Etodolac—ALB—Hemostasis—IFNA2—thyroid cancer	2.21e-05	0.000613	CbGpPWpGaD
Etodolac—ALB—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	2.2e-05	0.000609	CbGpPWpGaD
Etodolac—PTGS1—Metabolism—TPR—thyroid cancer	2.14e-05	0.000593	CbGpPWpGaD
Etodolac—RXRA—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	2.11e-05	0.000586	CbGpPWpGaD
Etodolac—PTGS1—Metabolism—PRKAR1A—thyroid cancer	2.11e-05	0.000584	CbGpPWpGaD
Etodolac—UGT2B7—Metabolism—RXRA—thyroid cancer	2.03e-05	0.000564	CbGpPWpGaD
Etodolac—PTGS2—Disease—TPR—thyroid cancer	2.03e-05	0.000563	CbGpPWpGaD
Etodolac—PTGS2—Disease—PRKAR1A—thyroid cancer	2e-05	0.000553	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism—SLC5A5—thyroid cancer	1.96e-05	0.000545	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—HPGD—thyroid cancer	1.96e-05	0.000543	CbGpPWpGaD
Etodolac—ALB—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	1.94e-05	0.000538	CbGpPWpGaD
Etodolac—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—thyroid cancer	1.91e-05	0.00053	CbGpPWpGaD
Etodolac—PTGS1—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	1.91e-05	0.000529	CbGpPWpGaD
Etodolac—PTGS2—Disease—MEN1—thyroid cancer	1.91e-05	0.000529	CbGpPWpGaD
Etodolac—ALB—Transmembrane transport of small molecules—RXRA—thyroid cancer	1.85e-05	0.000512	CbGpPWpGaD
Etodolac—RXRA—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	1.84e-05	0.000511	CbGpPWpGaD
Etodolac—RXRA—Developmental Biology—NRAS—thyroid cancer	1.84e-05	0.000511	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	1.84e-05	0.000511	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—TPR—thyroid cancer	1.7e-05	0.000471	CbGpPWpGaD
Etodolac—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—thyroid cancer	1.7e-05	0.000471	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—PRKAR1A—thyroid cancer	1.67e-05	0.000464	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism—RXRA—thyroid cancer	1.65e-05	0.000458	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	1.61e-05	0.000445	CbGpPWpGaD
Etodolac—PTGS1—Metabolism—SLC5A5—thyroid cancer	1.6e-05	0.000444	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	1.59e-05	0.000441	CbGpPWpGaD
Etodolac—RXRA—Developmental Biology—KRAS—thyroid cancer	1.58e-05	0.00044	CbGpPWpGaD
Etodolac—RXRA—Gene Expression—PPARG—thyroid cancer	1.54e-05	0.000427	CbGpPWpGaD
Etodolac—PTGS2—Disease—CALCA—thyroid cancer	1.52e-05	0.000421	CbGpPWpGaD
Etodolac—PTGS2—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	1.51e-05	0.00042	CbGpPWpGaD
Etodolac—UGT1A3—Metabolism—PPARG—thyroid cancer	1.51e-05	0.000418	CbGpPWpGaD
Etodolac—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	1.5e-05	0.000416	CbGpPWpGaD
Etodolac—PTGS2—Integrated Pancreatic Cancer Pathway—AKT1—thyroid cancer	1.43e-05	0.000398	CbGpPWpGaD
Etodolac—PTGS2—Disease—CDK1—thyroid cancer	1.37e-05	0.000381	CbGpPWpGaD
Etodolac—ALB—Metabolism—TPR—thyroid cancer	1.37e-05	0.000381	CbGpPWpGaD
Etodolac—ALB—Metabolism—PRKAR1A—thyroid cancer	1.35e-05	0.000375	CbGpPWpGaD
Etodolac—RXRA—Developmental Biology—HRAS—thyroid cancer	1.35e-05	0.000374	CbGpPWpGaD
Etodolac—PTGS1—Metabolism—RXRA—thyroid cancer	1.35e-05	0.000373	CbGpPWpGaD
Etodolac—PTGS1—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	1.31e-05	0.000363	CbGpPWpGaD
Etodolac—UGT2B7—Metabolism—PPARG—thyroid cancer	1.28e-05	0.000356	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—SLC5A5—thyroid cancer	1.27e-05	0.000353	CbGpPWpGaD
Etodolac—ALB—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	1.23e-05	0.00034	CbGpPWpGaD
Etodolac—RXRA—Metabolism—PPARG—thyroid cancer	1.2e-05	0.000332	CbGpPWpGaD
Etodolac—RXRA—Developmental Biology—AKT1—thyroid cancer	1.19e-05	0.00033	CbGpPWpGaD
Etodolac—UGT1A3—Metabolism—PTGS2—thyroid cancer	1.19e-05	0.000329	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—TPR—thyroid cancer	1.12e-05	0.000312	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—PRKAR1A—thyroid cancer	1.11e-05	0.000307	CbGpPWpGaD
Etodolac—PTGS2—Disease—NRG1—thyroid cancer	1.1e-05	0.000306	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—RXRA—thyroid cancer	1.07e-05	0.000296	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism—PPARG—thyroid cancer	1.04e-05	0.000289	CbGpPWpGaD
Etodolac—PTGS2—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	1.04e-05	0.000288	CbGpPWpGaD
Etodolac—UGT1A3—Metabolism—PTEN—thyroid cancer	1.03e-05	0.000287	CbGpPWpGaD
Etodolac—ALB—Platelet activation, signaling and aggregation—AKT1—thyroid cancer	1.03e-05	0.000286	CbGpPWpGaD
Etodolac—ALB—Metabolism—SLC5A5—thyroid cancer	1.03e-05	0.000285	CbGpPWpGaD
Etodolac—UGT2B7—Metabolism—PTGS2—thyroid cancer	1.01e-05	0.00028	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	1e-05	0.000278	CbGpPWpGaD
Etodolac—PTGS2—Disease—TERT—thyroid cancer	9.91e-06	0.000275	CbGpPWpGaD
Etodolac—ALB—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	9.64e-06	0.000267	CbGpPWpGaD
Etodolac—PTGS2—Disease—HIF1A—thyroid cancer	9.47e-06	0.000263	CbGpPWpGaD
Etodolac—RXRA—Metabolism—PTGS2—thyroid cancer	9.41e-06	0.000261	CbGpPWpGaD
Etodolac—UGT2B7—Metabolism—PTEN—thyroid cancer	8.8e-06	0.000244	CbGpPWpGaD
Etodolac—ALB—Metabolism—RXRA—thyroid cancer	8.64e-06	0.00024	CbGpPWpGaD
Etodolac—PTGS1—Metabolism—PPARG—thyroid cancer	8.5e-06	0.000236	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—SLC5A5—thyroid cancer	8.42e-06	0.000234	CbGpPWpGaD
Etodolac—ALB—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	8.41e-06	0.000233	CbGpPWpGaD
Etodolac—ALB—Hemostasis—NRAS—thyroid cancer	8.24e-06	0.000229	CbGpPWpGaD
Etodolac—RXRA—Metabolism—PTEN—thyroid cancer	8.21e-06	0.000228	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism—PTGS2—thyroid cancer	8.2e-06	0.000227	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	7.89e-06	0.000219	CbGpPWpGaD
Etodolac—PTGS2—Disease—BRAF—thyroid cancer	7.84e-06	0.000218	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism—PTEN—thyroid cancer	7.15e-06	0.000198	CbGpPWpGaD
Etodolac—ALB—Hemostasis—KRAS—thyroid cancer	7.09e-06	0.000197	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—RXRA—thyroid cancer	7.07e-06	0.000196	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	6.88e-06	0.000191	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—PPARG—thyroid cancer	6.75e-06	0.000187	CbGpPWpGaD
Etodolac—PTGS1—Metabolism—PTGS2—thyroid cancer	6.68e-06	0.000185	CbGpPWpGaD
Etodolac—ALB—Hemostasis—TP53—thyroid cancer	6.3e-06	0.000175	CbGpPWpGaD
Etodolac—RXRA—Gene Expression—AKT1—thyroid cancer	6.08e-06	0.000169	CbGpPWpGaD
Etodolac—ALB—Hemostasis—HRAS—thyroid cancer	6.03e-06	0.000167	CbGpPWpGaD
Etodolac—UGT1A3—Metabolism—AKT1—thyroid cancer	5.96e-06	0.000165	CbGpPWpGaD
Etodolac—PTGS1—Metabolism—PTEN—thyroid cancer	5.83e-06	0.000162	CbGpPWpGaD
Etodolac—PTGS2—Disease—PTEN—thyroid cancer	5.53e-06	0.000153	CbGpPWpGaD
Etodolac—ALB—Metabolism—PPARG—thyroid cancer	5.46e-06	0.000151	CbGpPWpGaD
Etodolac—ALB—Hemostasis—AKT1—thyroid cancer	5.32e-06	0.000148	CbGpPWpGaD
Etodolac—UGT2B7—Metabolism—AKT1—thyroid cancer	5.07e-06	0.000141	CbGpPWpGaD
Etodolac—PTGS2—Disease—NRAS—thyroid cancer	4.93e-06	0.000137	CbGpPWpGaD
Etodolac—RXRA—Metabolism—AKT1—thyroid cancer	4.73e-06	0.000131	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—PTEN—thyroid cancer	4.63e-06	0.000128	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—PPARG—thyroid cancer	4.47e-06	0.000124	CbGpPWpGaD
Etodolac—ALB—Metabolism—PTGS2—thyroid cancer	4.29e-06	0.000119	CbGpPWpGaD
Etodolac—PTGS2—Disease—KRAS—thyroid cancer	4.24e-06	0.000118	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism—AKT1—thyroid cancer	4.12e-06	0.000114	CbGpPWpGaD
Etodolac—ALB—Metabolism—PTEN—thyroid cancer	3.74e-06	0.000104	CbGpPWpGaD
Etodolac—PTGS2—Disease—HRAS—thyroid cancer	3.61e-06	0.0001	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—PTGS2—thyroid cancer	3.51e-06	9.75e-05	CbGpPWpGaD
Etodolac—PTGS1—Metabolism—AKT1—thyroid cancer	3.36e-06	9.32e-05	CbGpPWpGaD
Etodolac—PTGS2—Disease—AKT1—thyroid cancer	3.18e-06	8.83e-05	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—PTEN—thyroid cancer	3.06e-06	8.5e-05	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—AKT1—thyroid cancer	2.67e-06	7.4e-05	CbGpPWpGaD
Etodolac—ALB—Metabolism—AKT1—thyroid cancer	2.16e-06	5.98e-05	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—AKT1—thyroid cancer	1.77e-06	4.9e-05	CbGpPWpGaD
